Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.

Recent Articles By The Author

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Some Biotech Stocks to Add Exposure To

Some Biotech Stocks to Add Exposure To

Secondary offerings create buying opportunities.

Three Biotech Names to Consider

Three Biotech Names to Consider

A look at three names to consider in the biotech and biopharma space.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

4 Stocks You Should Be Watching This Earnings Season

4 Stocks You Should Be Watching This Earnings Season

Here are some smaller names I have my eye on as the season heats up.

Watch These 4 Stocks This Earnings Season

Watch These 4 Stocks This Earnings Season

Here are some smaller names I have my eye on.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Two to Buy on the Dip

Two to Buy on the Dip

Talk of intensifying trade war is creating some bargains for investors.